|Bid||74.25 x 1000|
|Ask||74.41 x 900|
|Day's Range||74.31 - 75.37|
|52 Week Range||56.01 - 90.17|
|Beta (5Y Monthly)||0.81|
|PE Ratio (TTM)||15.09|
|Earnings Date||Oct 20, 2020|
|Forward Dividend & Yield||4.80 (6.45%)|
|Ex-Dividend Date||Sep 23, 2020|
|1y Target Est||90.25|
Since 2008, Philip Morris Investments B.V. (PMIBV), a subsidiary of Philip Morris International (PMI) (NYSE: PM), has been a shareholder of Medicago (in which it currently holds an approximately one-third equity stake) and has supported Medicago’s innovative plant-derived research and development focused on vaccines. The investment is consistent with PMI’s own efforts to leverage science and innovation. Japan-based Mitsubishi Tanabe Pharma Corporation (MTPC) is the majority shareholder and PMIBV’s partner in Medicago. Among other things, PMIBV and MTPC will contribute additional funding to support Medicago’s efforts to develop a COVID-19 vaccine candidate.
Philip Morris (PM) delivers better-than-expected earnings results amid the coronavirus crisis.
Philip Morris International Inc. (NYSE:PM) just released its latest quarterly results and things are looking bullish...